Can-Fite reports patient cancer-free 10 years after trial

Ramat Gan, Israel - Can-Fite BioPharma Ltd., an Israeli biotech company, reported on Monday that a patient with advanced liver cancer participating in their completed Phase II trial of Namodenoson has now reached a ten-year overall survival rate and remains cancer-free. This patient had previously reported a complete response to the drug in November 2025.

The company initially announced a nine-year survival rate for this patient back in November 2025. Namodenoson, currently under evaluation in a randomized, double-blind, placebo-controlled pivotal Phase III study for advanced hepatocellular carcinoma in patients with Child-Pugh B7 cirrhosis, showed a survival rate for this patient that exceeded expectations based on the study's design assumptions, according to a September 2, 2026 announcement.

The Phase III study of Namodenoson remains blinded, and the survival data includes both patients who received the drug and those who received a placebo. The company plans to assess treatment-specific efficacy through a planned analysis.

Namodenoson is a small, orally bioavailable drug that targets the A3 adenosine receptor. The drug has received Orphan Drug Designation in the U.S. and Europe, and Fast Track Designation as a second-line treatment for hepatocellular carcinoma from the U.S. Food and Drug Administration. Can-Fite BioPharma, a clinical-stage biotechnology company, is developing small molecule drugs targeting oncological and inflammatory diseases, with its lead drug Piclidenoson currently in a pivotal Phase III study for plaque psoriasis, with interim results expected in Q1 2027.